VEGFA Mouse Monoclonal Antibody [Clone ID: OTI4E3]
CAT#: TA500289
VEGFA (VEGF) mouse monoclonal antibody, clone OTI4E3 (formerly 4E3)
Size: 30 ul
Formulation: Carrier Free
Specifications
Product Data | |
Clone Name | OTI4E3 |
Applications | IF, WB |
Recommended Dilution | WB: 1:200 - 1:1000, IHC 1:50, IF 1:100 |
Reactivities | Human |
Host | Mouse |
Isotype | IgG1 |
Clonality | Monoclonal |
Immunogen | Human recombinant protein fragment corresponding to amino acids 27-233 of human VEGFA (NP_003367) produced in E.coli. |
Formulation | PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide. |
Concentration | 1 mg/ml |
Purification | Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) |
Conjugation | Unconjugated |
Storage | Store at -20°C as received. |
Stability | Stable for 12 months from date of receipt. |
Predicted Protein Size | 23.8 kDa |
Gene Name | vascular endothelial growth factor A |
Database Link | |
Background | VEGF is a member of the PDGF/VEGF growth factor family that is often found as a disulfide linked homodimer. It is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in VEGF gene have been associated with proliferative and nonproliferative diabetic retinopathy. |
Synonyms | MVCD1; VEGF; VPF |
Reference Data | |
Protein Families | Druggable Genome, Secreted Protein |
Protein Pathways | Bladder cancer, Cytokine-cytokine receptor interaction, Focal adhesion, mTOR signaling pathway, Pancreatic cancer, Pathways in cancer, Renal cell carcinoma, VEGF signaling pathway |
Documents
Product Manuals |
FAQs |
SDS |
Resources
Antibody Resources |
{0} Product Review(s)
Be the first one to submit a review